blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3796934

EP3796934 - BISPECIFIC T CELL ENGAGER AND USES THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  26.02.2021
Database last updated on 09.09.2024
FormerThe international publication has been made
Status updated on  30.11.2019
Most recent event   Tooltip01.06.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
MANYSMART THERAPEUTICS, INC.
No. 236, Minzu W. Road
Datong Dist.
Taipei City 10375 / TW
[2021/13]
Inventor(s)01 / HUANG, Hsin-Yi
4f., No. 236, Minzu W. Rd. Datong Dist.
Taipei City, 10375 / TW
02 / LIAO, Cheng Hao
4f., No. 236, Minzu W. Rd. Datong Dist.
Taipei City, 10375 / TW
 [2021/13]
Representative(s)2K Patentanwälte Blasberg Kewitz & Reichel
Partnerschaft mbB
Schumannstrasse 27
60325 Frankfurt am Main / DE
[2021/13]
Application number, filing date19806758.923.05.2019
[2021/13]
WO2019US33752
Priority number, dateUS201862675208P23.05.2018         Original published format: US 201862675208 P
[2021/13]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019226894
Date:28.11.2019
Language:EN
[2019/48]
Type: A1 Application with search report 
No.:EP3796934
Date:31.03.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 28.11.2019 takes the place of the publication of the European patent application.
[2021/13]
Search report(s)International search report - published on:US28.11.2019
(Supplementary) European search report - dispatched on:EP09.03.2022
ClassificationIPC:A61K39/395, C07K16/28, C07K19/00, C12N1/15, C12N1/21, C12N5/10, C12N15/63, C12P21/02, A61K39/44, A61P31/22, A61P35/00, C07K14/735, C07K16/08, C07K16/32
[2022/14]
CPC:
C07K14/70535 (EP,KR,US); C07K16/2809 (EP,KR,US); A61K38/00 (KR);
A61K39/44 (EP); A61P31/22 (EP,US); A61P35/00 (EP,KR,US);
A61P35/02 (EP); A61P37/06 (KR); C07K16/085 (EP);
C07K16/2827 (EP); C07K16/283 (EP); C07K16/2863 (EP);
C07K16/2887 (EP); C07K16/32 (EP); C12N15/62 (EP);
A61K2039/505 (EP,US); A61K2039/507 (EP); A61K2039/5256 (EP);
A61K2039/585 (EP); C07K2317/24 (EP); C07K2317/622 (EP,KR,US);
C07K2317/73 (EP); C07K2317/732 (KR,US); C07K2319/00 (KR);
C07K2319/02 (EP,KR,US); C07K2319/21 (EP,KR); C07K2319/32 (EP);
C07K2319/33 (EP); C12N2750/14143 (EP,KR) (-)
Former IPC [2021/13]A61K39/395, C07K16/28, C07K19/00, C12N1/15, C12N1/21, C12N5/10, C12N15/63, C12P21/02
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/13]
TitleGerman:BISPEZIFISCHER T-ZELL-ENGAGER UND VERWENDUNGEN DAVON[2021/13]
English:BISPECIFIC T CELL ENGAGER AND USES THEREOF[2021/13]
French:ACTIVATEUR DE LYMPHOCYTES T BISPÉCIFIQUE ET SES UTILISATIONS[2021/13]
Entry into regional phase03.12.2020National basic fee paid 
03.02.2021Search fee paid 
03.12.2020Designation fee(s) paid 
03.12.2020Examination fee paid 
Examination proceduredeletedDeletion: Application deemed to be withdrawn, date of legal effect  [2021/13]
03.12.2020Examination requested  [2021/13]
02.02.2021Despatch of communication that the application is deemed to be withdrawn, reason: filing fee / search fee not paid in time  [2021/13]
21.09.2022Amendment by applicant (claims and/or description)
Request for further processing for:The application is deemed to be withdrawn due to non-payment of the search fee
03.02.2021Request for further processing filed
03.02.2021Full payment received (date of receipt of payment)
Request granted
19.02.2021Decision despatched
Fees paidRenewal fee
31.05.2021Renewal fee patent year 03
31.03.2022Renewal fee patent year 04
31.03.2023Renewal fee patent year 05
31.05.2024Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XYI]WO2016094456  (1GLOBE HEALTH INST LLC [US]) [X] 1-10,12-15 * paragraph [0082]; figure 1; claims 1-3,6-9 * [Y] 2,8 [I] 11;
 [Y]WO2018027135  (UNUM THERAPEUTICS INC [US]) [Y] 2,8* claims 1,6 *
International search[Y]US2004146889  (DOWDY STEVEN F [US], et al) [Y] 9, 15 * ; paragraphs [0013], [0026] *;
 [Y]US2007207145  (OWENS S MICHAEL [US], et al) [Y] 8 * ; paragraph [0039] *;
 [A]US2013078236  (MARY CAROLINE [FR], et al) [A] 14* ; paragraph [0039] *;
 [Y]US2015139943  (CAMPANA DARIO [SG], et al) [Y] 1-9, 11-12, 15, 17-25 * ; abstract; paragraphs [0015], [0019], [0020], [0023], [0026], [0056], [0061], [0111], [0112], [0114], [0124], [0145], [0148] *;
 [Y]WO2016178996  (UNIV CALIFORNIA [US]) [Y] 17, 19 * ; page 34, lines 1-2; page 27, lines 17-26 *;
 [Y]WO2018022957  (TARVEDA THERAPEUTICS INC [US]) [Y] 1-9, 11-12, 15, 17-25 * ; [0056] *;
 [Y]US2018057795  (CHILDS RICHARD W [US], et al) [Y] 12 * ; paragraph [0037] *
by applicantWO2016094456
 WO2018027135
    - ALMAGRO et al., Front Immunol, (20170000), vol. 8, page 1751
    - SUBRAMANIAN et al., Cancer Management and Research, (20170000), vol. 9, pages 131 - 140
    - VAN DE DONK et al., Blood, (20180000), vol. 131, pages 13 - 29
    - K. CHIN et al., Annals of Oncology, (20170000), vol. 28, pages 1658 - 1666
    - HAMILTONRATH, Expert Opinion on Biological Therapy, (20170000), vol. 17, pages 515 - 523
    - SUZUKI et al., J Toxicol Pathol, (20150000), vol. 28, pages 133 - 139
    - HIDDEMANN et al., Blood, (20050000), vol. 106, pages 3725 - 32
    - POSTOW et al., J Clin Oncol, (20150000), vol. 33, pages 1974 - 1982
    - WANG et al., Front Immunol, (20150000), vol. 6, page 368
    - CARTRON et al., Blood, (20020000), vol. 99, pages 754 - 758
    - KIM et al., Blood, (20060000), vol. 108, pages 2720 - 2725
    - ZHANG et al., J Clin Oncol, (20070000), vol. 25, pages 3712 - 3718
    - MUSOLINO et al., J Clin Oncol, (20080000), vol. 26, pages 1789 - 1796
    - VEERAMANI et al., Blood, (20110000), vol. 118, pages 3347 - 3349
    - MELLOR et al., J Hematol Oncol, (20130000), vol. 6, page 1
    - GONNET et al., Science, (19920000), vol. 256, pages 1443 - 1445
    - ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, pages 403 - 410
    - ALTSCHUL et al., Nucleic Acids Res., (19970000), vol. 25, pages 3389 - 402
    - REINEKE, Methods Mol Biol, (20040000), vol. 248, pages 443 - 463
    - TOMER, Protein Science, (20000000), vol. 9, pages 487 - 496
    - EHRING, Analytical Biochemistry, (19990000), vol. 267, no. 2, pages 252 - 259
    - ENGENSMITH, Anal. Chem., (20010000), vol. 73, pages 256A - 265A
    - POWELL et al., "Compendium of excipients for parenteral formulations", J Pharm Sci Technol, (19980000), vol. 52, pages 238 - 311, XP009119027
    - MORDENTI et al., Pharmaceut. Res., (19910000), vol. 8, page 1351
    - WU et al., J. Biol. Chem., (19870000), vol. 262, pages 4429 - 4432
    - SEFTON, CRC Crit. Ref. Biomed. Eng., (19870000), vol. 14, page 201
    - GOODSON, Medical Applications of Controlled Release, (19840000), vol. 2, pages 115 - 138
    - LANGER, Science, (19900000), vol. 249, pages 1527 - 1533
    - PARDOLL, Nat Rev Cancer, (20120000), vol. 12, pages 252 - 264
    - TOPALIAN et al., Curr Opin Immunol, (20120000), vol. 24, pages 207 - 212
    - BOYERINAS et al., Cancer Immunol Res, (20150000), vol. 3, pages 1148 - 1157
    - HAYNES et al., N Engl J Med, (20120000), vol. 366, pages 1275 - 1286
    - PARSONS et al., Retrovirology, (20180000), vol. 15, page 58
    - MADHAVI et al., J Virol, (20170000), vol. 91, pages e00700 - 17
    - GAO et al., Human Vaccines Immunotherapeutics, (20170000), vol. 13, pages 1768 - 1773
    - COGHILL et al., Clin Cancer Res, (20160000), vol. 22, pages 3451 - 3457
    - MCVOY et al., Int J Mol Sci, (20180000), vol. 19, page 3982
    - SHEEHY et al., J Immunol Methods, (20010000), vol. 249, pages 99 - 110
    - CHEN et al., Clinical Immunology, (20020000), vol. 104, pages 58 - 66
    - AHMED et al., JCI Insight, (20180000), vol. 3, page e97805
    - ZHOU et al., Blood, (20120000), vol. 120, pages 4334 - 4342
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.